Актуальные вопросы интерферонотерапии


Б.М. Блохин, А.Д. Прохорова, А.С. Суюндукова

Кафедра поликлинической и неотложной педиатрии ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н И. Пирогова» Минздрава России
Одну из ключевых ролей в иммунорегуляции играет система интерферона (ИФН). Она включает механизмы врожденного и адаптивного иммунного ответа, является первой линией защиты от вирусных и других внутриклеточных инфекций, участвует в поддержании гомеостаза организма. Терапевтический потенциал препаратов интерферонов в настоящее время находится в зоне особого внимания. Данные различных исследований, приведенных в статье, подтверждают необходимость формирования четких показаний для назначения этой группы препаратов. Клиницистам важно строго оценивать клинические риски и преимущества при назначении интерферонотерапии.

Литература


  1. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev. 2001 Oct; 14(4): 778–809, table of contents.
  2. Bandurska K., Król I., Myga-Nowak M. Interferons: between structure and function. Postepy Hig Med Dosw (Online). 2014 May 6; 68: 428–40.
  3. Ершов Ф.И., Наровлянский А.Н. Основные итоги изучения системы интерферона к 2011 году. В сборнике Интерферон-2011. Под ред. акад. РАМН, проф. Ф.И. Ершова и проф. А.Н. Наровлянского. Москва, 2012. С. 14–34.
  4. Park S.H., Kang K., Giannopoulou E. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat Immunol. 2017 Oct; 18(10): 1104–16.
  5. Lachová V., Škorvanová L., Svetlíková D. et al. Comparison of transcriptional profiles of interferons, CXCL10 and RIG-1 in influenza infected A549 cells stimulated with exogenous interferons. Acta Virol. 2017; 61(2): 183–90.
  6. Малиновская В.В. Онтогенез системы интерферона и проблемы терапии в неонатальном периоде. В сборнике Интерферон-2011. Под ред. акад. РАМН, проф. Ф.И. Ершова и проф. А.Н. Наровлянского. Москва, 2012. С. 35–51.
  7. Sheng Y.J., Xu S.S., Li X.J. et al. Low birth weight contributed to increased serum IL-6 levels in infantile respiratory syncytial virus infection. BMC Pediatr. 2017 Dec 16; 17(1): 205.
  8. Frémond M.L., Uggenti C., Van Eyck L. et al. Brief Report: Blockade of TANK-Binding Kinase 1/IKK Inhibits Mutant Stimulator of Interferon Genes (STING)-Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells. Arthritis Rheumatol. 2017 Jul; 69(7): 1495–501.
  9. Maughan A. Ogbuagu. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. O.Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2): 219–27.
  10. Herrington-Symes A., Choi J.W., Brocchini S. Interferon dimers: IFN-PEG-IFN. J Drug Target. 2017 Nov - Dec; 25(9–10): 881–90.
  11. Ершов Ф.И., Шульдяков А.А., Романцов М.Г., Ляпина Е.П., Соболева Л.А. Результаты и перспективы использования индукторов интерферона в лечении инфекционных болезней. Вестник Российской академии медицинских наук. 2013; 10: 46–52.
  12. Zhang K.J., Yin X.F., Yang Y.Q. et al. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Clin Cancer Res. 2017 Apr 15; 23(8): 2038–49.
  13. Rizza P., Moretti F., Capone I., Belardelli F. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 2015 Apr; 26(2): 195–201.
  14. Мухачева М.В., Бейн Б.Н. Роль интерферонов в иммунитете у больных с церебральными опухолями. Фундаментальные исследования. 2015; 1–7: 1486–1490.
  15. Симоненко В.Б., Дулин П.А., Маканин М.А. Возможности таргетной терапии нейроэндокринных опухолей. Клиническая медицина. 2014; 92(8): 5–14.
  16. Глазкова Н.Н. Иммуномодуляторы в лечении рака. Вестник Калужского университета. 2016; 2: 18–28.
  17. Tong R., Feng L, Zhang L. et al. Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis. J Interferon Cytokine Res. 2015 Dec; 35(12): 963–68.
  18. Buoncervello M., Romagnoli G., Buccarelli M. et al. IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget. 2016 May 3; 7(18): 26361–73. Doi: 10.18632/oncotarget.8379.
  19. Liu X., Lu J., He M.L. et al. Antitumor effects of interferon-alpha on cell growth and metastasis in human nasopharyngeal carcinoma. Curr Cancer Drug Targets. 2012 Jun; 12(5): 561–70.
  20. 2Yin H., Chen N., Guo R. et al. Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Sci Rep. 2015 Nov 20; 5: 16975.
  21. Skov V., Riley C.H., Thomassen et al. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms./ M,Leuk Lymphoma. 2017 Aug; 58(8): 1914–21.
  22. Šantak G., Šantak M., Forčić D. Comparison of antitumor effects of native and recombinant human interferon-α on non-small cell lung cancer cells. Anticancer Res. 2013 May; 33(5): 2043–46.
  23. Абатуров А.Е., Юлиш Е.И. Роль интерферонов в защите респираторного тракта. Часть 2. Механизмы действия интерферонов. Здоровье ребенка. 2007; 6: 136–144.
  24. Ghodke-Puranik Y., Dorschner J.M., Vsetecka D.M. et al. Lupus-Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. Arthritis Rheumatol. 2017 Dec; 69(12): 2328–37.
  25. Imran M., Waheed Y., Manzoor S. et al. Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol J. 2012 Jun 22; 9: 126.
  26. Rönnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98): 21–4.
  27. Torigoe M., Iwata S., Nakayamada S. et al. Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27-IgD- Cells. J Immunol. 2017 Jul 15; 199(2): 425–34.
  28. Jin Z., Fan J, Zhang Y. et al. Comparison of morphology, phenotypes and function between cultured human IL‑4‑DC and IFN‑DC. Mol Med Rep. 2017 Nov; 16(5): 7345–54.
  29. Murayama G., Furusawa N., Chiba A. et al. Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2017 Oct 19; 19(1): 234.
  30. Imgenberg-Kreuz J., Sandling J.K., Björk A. et al. Transcription profiling of peripheral B cells in antibody-positive primary Sjögren’s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol. 2018 May; 87(5): e12662.
  31. Ghodke-Puranik Y., Dorschner J.M., Vsetecka D.M. et al. Lupus-Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells. Arthritis Rheumatol. 2017 Dec; 69(12): 2328–37.
  32. Sossau D., Kofler L., Eigentler T. Type 1 diabetes mellitus caused by treatment with low-dose interferon-α in a melanoma patient. Melanoma Res. 2017 Oct; 27(5): 516–18.
  33. Lombardi A., Tsomos E., Hammerstad S.S., Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018 Aug 14. pii: S0896-8411(18)30323-8.
  34. Khan W.A., Qureshi J.A. Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b. APMIS. 2015 Dec; 123(12): 1016–24.
  35. Heim M.H. Innate immunity and HCV. J Hepatol. 2013 Mar; 58(3): 564–74.
  36. Haldipur B., Bhukya P.L., Arankalle V., Lole K. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122. J Virol. 2018 May 14; 92(11). pii: e01999-17.
  37. Davidson S., McCabe T.M., Crotta S. et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med. 2016 Sep 1; 8(9): 1099–112.
  38. Como C.N., Pearce C.M., Cohrs R.J., Baird N.L. Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons. Virology. 2018 Sep; 522: 13–8.
  39. Tang L.S.Y., Covert E., Wilson E., Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA. 2018 May 1; 319(17): 1802–13.
  40. Friedman A., Siewe N. Chronic hepatitis B virus and liver fibrosis: A mathematical model. PLoS One. 2018 Apr 10; 13(4): e0195037.
  41. Maughan A., Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2): 219–27.
  42. Hayden F.G., de Jong M.D. Emerging influenza antiviral resistance threats. J Infect Dis. 2011 Jan 1; 203(1): 6–10.
  43. Betakova T., Kostrabova A., Lachova V., Turianova L. Cytokines Induced During Influenza Virus Infection. Curr Pharm Des. 2017; 23(18): 2616–22.
  44. Lee S., Hirohama M., Noguchi M. et al. Influenza A Virus Infection Triggers Pyroptosis and Apoptosis of Respiratory Epithelial Cells through the Type I Interferon Signaling Pathway in a Mutually Exclusive Manner. J Virol. 2018 Jun 29; 92(14). pii: e00396–18.
  45. Shepardson K.M., Larson K., Morton R.V. et al. Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection. MBio. 2016 May 3; 7(3). pii: e00506–16.
  46. Rynda-Apple A., Robinson K.M., Alcorn J.F. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease. Infect Immun. 2015 Oct; 83(10): 3764–70.
  47. Robinson K.M., Kolls J.K., Alcorn J.F. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 2015 Jun; 34: 59–67.
  48. Rynda-Apple A., Harmsen A., Erickson A.S. et al. Regulation of IFN-γ by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia. Eur J Immunol. 2014 Nov; 44(11): 3263–72.
  49. Carolan L.A., Rockman S., Borg K. et al. Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses. J Virol. 2015 Dec 30; 90(6): 2838–48.
  50. Sobrevilla-Navarro A.A., Sandoval-Rodríguez A., García-Bañuelos J.J. et al. Interferon-α Silencing by Small Interference RNA Increases Adenovirus Transduction and Transgene Expression in Huh7 Cells. Mol Biotechnol. 2018 Apr; 60(4): 251–58.
  51. Xia C., Wolf J.J., Vijayan M. et al. Casein Kinase 1α Mediates the Degradation of Receptors for Type I and Type II Interferons Caused by Hemagglutinin of Influenza A Virus. J Virol. 2018 Mar 14; 92(7). pii: e00006–18.
  52. Jiang H., Shen S.M., Yin J. et al. Influenza virus non-structural protein 1 inhibits the production of interferon β of alveolar epithelial cells upon the infection of influenza A H1N1. Mol Med Rep. 2017 Oct; 16(4): 4553–60.
  53. Song J., Hu Y., Li J. et al. Suppression of the toll-like receptor 7-dependent type I interferon production pathway by autophagy resulting from enterovirus 71 and coxsackievirus A16 infections facilitates their replication. Arch Virol. 2018 Jan; 163(1): 135–44.
  54. Akiyama H., Ramirez N.P., Gibson G. et al. Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. Gummuluru S4.J Virol. 2017 Oct 13; 91(21). pii: e00972–17.
  55. Narulla M.S., Alasiri A., Charmier L. et al. Positive and Negative Regulation of Type I Interferons by the Human T Cell Leukemia Virus Antisense Protein HBZ. J Virol. 2017 Sep 27; 91(20). pii: e00853–17.
  56. Cánepa C., Imperiale J.C., Berini C.A. et al. Development of a Drug Delivery System Based on Chitosan Nanoparticles for Oral Administration of Interferon-α. Biomacromolecules. 2017 Oct 9; 18(10): 3302–09.
  57. Elbaz T., Elserafy M., Elakel W. et al. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res. 2017 Aug; 37(8): 348–53.
  58. Weber E., Reynaud Q., Fort R. et al. Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review and meta-analysis of 28 studies. Medicine (Baltimore). 2017 Sep; 96(37): e7534.
  59. Ragusa R., Bertino G., Bruno A. et al. Evaluation of health status in patients with hepatitis c treated with and without interferon. Health Qual Life Outcomes. 2018 Jan 17; 16(1):17.
  60. Bołończyk Ł., Siekierska-Hellmann M., Wiśniewski P. et al. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study. Postepy Hig Med Dosw (Online). 2017 Sep 25; 71(0): 842–49.
  61. Sayiner Z.A., Eraydın A., Metin T., Özkaya M. Interferon alpha-induced non-immune thyrotoxicosis treated by plasmapheresis./ BMJ Case Rep. 2017 Sep 25; 2017. pii: bcr-2017–221228.
  62. Jain V., Patel R.K., Kapadia Z. et al. Drugs and hyperglycemia: A practical guide. Maturitas. 2017 Oct; 104: 80–3.
  63. Silva J.L., Faria D.S., Teixeira F., Afonso M.C., Peixoto D. Systemic sclerosis induced by interferon-alfa treatment of melanoma. Acta Reumatol Port. 2017 Jul–Sep; 42(3): 263–64.
  64. Mendieta K.L., Irfan M., Fernandez Faith E. Interferon-alpha induced psoriasis in a teenager. Pediatr Dermatol. 2018 Mar; 35(2): e136–e137.
  65. Fortuna G., Aria M., Schiavo J.H. Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. Eur J Clin Pharmacol. 2017 Dec; 73(12): 1523–37. Doi: 10.1007/s00228-017-2325-0.
  66. Lee G.A., Hess L., Glasson W.J., Whitehead K. Topical Interferon Alpha-2b Induced Reactive Lymphoid Hyperplasia Masquerading as Orbital Extension of Ocular Surface Squamous Neoplasia. Cornea. 2018 Jun; 37(6): 796–98.
  67. Khan Faisal A.W., Nisar S., Ali S.A., Ahmad F. Effects Of Interferon Therapy On Heart. J Ayub Med Coll Abbottabad. 2016 Apr–Jun; 28(2): 276–80.
  68. Cubas-Gaona L.L., Diaz-Beneitez E., Ciscar M. et al. Exacerbated Apoptosis of Cells Infected with Infectious Bursal Disease Virus upon Exposure to Interferon Alpha. J Virol. 2018 May 14; 92(11). pii: e00364-18.


Об авторах / Для корреспонденции


Борис Моисеевич Блохин, д.м.н., проф., зав. кафедрой поликлинической и неотложной педиатрии педиатрического факультета ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России. Адрес: 117997, г. Москва, ул. Островитянова, д. 1. Тел.: 8 (916) 182-82-07. E-mail: blokhinb@gmail.com
Анастасия Дмитриевна Прохорова, ассистент кафедры поликлинической и неотложной педиатрии педиатрического факультета ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России. Адрес: 117997, г. Москва, ул. Островитянова, д. 1. Тел.: 8 (916) 689-50-38. E-mail: prohorovaa525@gmail.com
Алия Сагитовна Суюндукова, к.м.н., доцент кафедры поликлинической и неотложной педиатрии педиатрического факультета ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России. Адрес: 117997, г. Москва, ул. Островитянова, д. 1. Тел.: 8 (926) 317-10-26. E-mail: a.s.suyundukova@hotmail.com


Похожие статьи


Бионика Медиа